Despite that, about 25–30% of metastatic BC (MBC) previously treated with ET develop resistance due to alterations in the estrogen receptor (ER) ligand-binding domain, showing a ligand-independent ER activity and in particular, up to 20% develop mutations in the ER gene (ESR1) (4–7). Here, ESR1 is linked to breast cancer.